Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV)
Pathogens · 2024
DOI: 10.3390/pathogens13090804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Nima D Badizadegan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kid Risk, Inc., Orlando, FL 32819, USA. Hauptthemen laut MEDLINE: Poliomyelitis, Poliovirus Vaccine, Oral, Poliovirus, Disease Eradication. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CDC HHS, Centers for Disease Control and Prevention.
Abstract (Originalsprache)
In 2022, global poliovirus modeling suggested that coordinated cessation of bivalent oral poliovirus vaccine (bOPV, containing Sabin-strain types 1 and 3) in 2027 would likely increase the risks of outbreaks and expected paralytic cases caused by circulating vaccine-derived polioviruses (cVDPVs), particularly type 1. The analysis did not include the implementation of planned, preventive supplemental immunization activities (pSIAs) with bOPV to achieve and maintain higher population immunity for types 1 and 3 prior to bOPV cessation. We reviewed prior published OPV cessation modeling studies to support bOPV cessation planning. We applied an integrated global poliovirus transmission and OPV evolution model after updating assumptions to reflect the epidemiology, immunization, and polio eradication plans through the end of 2023. We explored the effects of bOPV cessation in 2027 with and without additional bOPV pSIAs prior to 2027. Increasing population immunity for types 1 and 3 with bOPV pSIAs (i.e., intensification) could substantially reduce the expected global risks of experiencing cVDPV outbreaks and the number of expected polio cases both before and after bOPV cessation. We identified the need for substantial increases in overall bOPV coverage prior to bOPV cessation to achieve a high probability of successful bOPV cessation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kid Risk, Inc., Orlando, FL 32819, USA.
- Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
ORCID-Profile: Kimberly M Thompson
Förderung
- CDC HHS
- Centers for Disease Control and Prevention
Zitieren
APA
Badizadegan, N. D., Wassilak, S. G. F., Estívariz, C. F., Wiesen, E., Burns, C. C., Bolu, O., & Thompson, K. M. (2024). Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV). Pathogens. https://doi.org/10.3390/pathogens13090804
Vancouver
Badizadegan ND, Wassilak SGF, Estívariz CF, Wiesen E, Burns CC, Bolu O, et al. Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV). Pathogens. 2024. doi:10.3390/pathogens13090804
BibTeX
@article{Badizadegan2024,
author = {Badizadegan, Nima D and Wassilak, Steven G F and Estívariz, Concepción F and Wiesen, Eric and Burns, Cara C and Bolu, Omotayo and Thompson, Kimberly M},
title = {Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV)},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13090804}
}
EUVIMED